Market Research Is Too Slow for the AI Era, so Brox Built 60,000 Identical 'Digital Twins' Of Real People You Can Survey Instantly, Repeatedly

Why It Matters

It gives Fortune‑500s real‑time, psychologically grounded data for rapid decision‑making, cutting months off research timelines. This could reshape how banks and drug makers assess risk and consumer reaction.

Key Takeaways

• 60,000 digital twins replicate real individuals with deep interview data.
• Platform delivers survey results within hours, not weeks.
• Subscription model starts at $100,000 annual fee.
• Focus sectors: pharmaceuticals and finance risk modeling.
• Provides reasoning chains explaining each predicted behavior.

Pulse Analysis

The speed of consumer sentiment has outpaced traditional market‑research methods. A viral TikTok can shift brand perception in hours, yet conventional surveys still require 12 weeks to recruit respondents, field questionnaires and compile results. Brox confronts this mismatch by assembling a pre‑built audience of 60,000 digital twins—exact replicas of real people gathered through exhaustive, consent‑driven interviews. Because the data set already exists, enterprises can query the population instantly, turning what used to be a quarterly cadence into a matter of hours.

What sets Brox apart is the fidelity of its inputs. Unlike competitors that generate purely synthetic personas with large language models, each twin carries up to 300 pages of personal history, decision drivers and psychological context. The platform’s AI layer does not merely output a probability; it produces a step‑by‑step reasoning chain that reveals why a high‑net‑worth individual might withdraw deposits after a geopolitical shock. This transparency satisfies both compliance teams and senior strategists who need more than a statistical average.

The business model reflects the premium nature of the offering. Subscriptions start at $100,000 a year and can rise to $1.5 million for global, unlimited access, positioning Brox as an enterprise SaaS rather than a per‑respondent vendor. Early adopters in pharma and finance are already using the service to gauge vaccine hesitancy and predict depositor behavior under stress scenarios. Backed by Scribble Ventures, Wonder Ventures and Vela Partners, Brox’s human‑first data moat could force the broader research industry to accelerate its own AI integration or risk obsolescence.